| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
1 Pfizer Pharma GmbH, Karlsruhe, Germany, 2 Department of Neurosurgery, University of Erlangen-Nuernberg, Erlangen, Germany, 3 Endokrinologische Praxis, Oldenburg, Germany, 4 Division of Endocrinology, Department of Internal Medicine, University of Essen, Essen, Germany and 5 Division of Clinical Endocrinology, Department of Gastroenterology, Hepatology and Endocrinology, Charité-Universitätsmedizin, Schumannstr, 20/21, 10117, Berlin, Germany
(Correspondence should be addressed to C J Strasburger; Email: christian.strasburger{at}charite.de)
Objective: The GH receptor antagonist pegvisomant is a highly effective new treatment option in acromegaly. The German Pegvisomant Observational Study (GPOS) was started to monitor long-term safety and efficacy of pegvisomant as prescribed in clinical practice.
Design: GPOS is an observational, multi-center, surveillance study, which comprises non-interventional data collection.
Methods: Of the 229 patients included in the study, 90.4% had previous pituitary surgery, 43.2% were treated by radiation therapy, and 94.3% had previous medical therapy for acromegaly that had been discontinued mainly due to persistent IGF-I elevation or side effects. The intention-to-treat population included 177 patients with at least one post-baseline efficacy measurement.
Results: IGF-I levels decreased from 1.75±0.91-fold the upper limit of normal at baseline to 1.05± 0.62 at the 6-month visit, 0.96±0.60 at the 12-month visit, and to 0.89±0.41-fold after 24 months (P<0.0001). Mean duration of pegvisomant therapy was 51.8±35.8 weeks (median=51.9 weeks). IGF-I was normalized in 64.4% at 6 months with a median dose of 15.0 mg/day, in 70.9% at 12 months, and in 76.3% at 24 months. Fasting glucose levels improved from 114.4±45.9 to 101.5± 42.8 mg/dl after 6 months (P<0.01) and to 100.6±33.2 mg/ml after 12 months (P<0.01). General physical condition measured by specific signs and symptoms score improved significantly. Adverse events occurring in >1% were injection site reactions in 7.4%, elevated liver enzymes (>3 times of normal) in 5.2% (3.1% spontaneously normalized during continued treatment), reported increase of pituitary tumor volume in 5.2% (which was verified in 3.1%), and headache in 1.7%.
Conclusions: Pegvisomant is generally well tolerated with a safety profile similar to that reported in clinical trials and can effectively reduce IGF-I in patients with acromegaly refractory to conventional therapy.
This article has been cited by other articles:
|
|
 |
|
  M Buchfelder, D Weigel, M Droste, K Mann, B Saller, K Brubach, G K Stalla, M Bidlingmaier, C J Strasburger, and on behalf of the investigators of the German Pegvi Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study Eur. J. Endocrinol., July 1, 2009; 161(1): 27 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, et al. Guidelines for Acromegaly Management: An Update J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Neggers, W. de Herder, J. Janssen, R. Feelders, and A. van der Lely Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients Eur. J. Endocrinol., April 1, 2009; 160(4): 529 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N. G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy Eur. J. Endocrinol., April 1, 2009; 160(4): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jimenez, P. Burman, R. Abs, D. R Clemmons, W. M Drake, K. R Hutson, M. Messig, M. O Thorner, P. J Trainer, and R. F Gagel Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials Eur. J. Endocrinol., November 1, 2008; 159(5): 517 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Higham and P. J. Trainer Growth hormone excess and the development of growth hormone receptor antagonists Exp Physiol, November 1, 2008; 93(11): 1157 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, R. Pivonello, R. S Auriemma, M. Galdiero, S. Savastano, and G. Lombardi Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly Eur. J. Endocrinol., November 1, 2007; 157(5): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
